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Abstract 
Objectives: Attribution of symptoms as medication side-effects is informed by pre-
existing beliefs about medicines and perceptions of personal sensitivity to their effects 
(pharmaceutical schemas). We tested whether 1) pharmaceutical schemas were associated with 
memory (recall/recognition) for side-effect information 2) memory explained the attribution of a 
common unrelated symptom as a side-effect.  
Design: In this analogue study participants saw the patient leaflet of a fictitious asthma 
drug listing eight side-effects. 
Main outcome measures: We measured recall and recognition memory for side-effects 
and used a vignette to test whether participants attributed an unlisted common symptom 
(headache) as a side-effect. 
Results: Participants who perceived pharmaceuticals as more harmful in general recalled 
fewer side-effects correctly (r Correct Recall=-.273), were less able to differentiate between listed and 
unlisted side-effects (r Recognition Sensitivity=-.256) and were more likely to attribute the unlisted 
headache symptom as a side-effect (r side-effect attribution=.381, ps<.01). The effect of harm beliefs on 
side-effect attribution was partially mediated by correct recall of side-effects. 
Conclusion: Pharmaceutical schemas are associated with memory for side-effect 
information. Memory may explain part of the association between pharmaceutical schemas and 
the attribution of unrelated symptoms as side-effects. 
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Introduction 
Pharmaceutical medicines are fundamental to the management of most long-term 
conditions, but optimal treatment outcomes are compromised by side-effects and non-adherence 
(Sabaté, 2003). Virtually all medicines can cause side-effects, but not all the symptoms that 
patients attribute as medication side-effects have a clear pharmacological grounding (Nestoriuc, 
Orav, Liang, Horne, & Barsky, 2010). Research on the nocebo effect shows for example that 
patients’ expectations of side-effects can increase side-effect reporting even when patients are 
actually taking pharmacologically inactive placebo (Colloca & Miller, 2011; Faasse & Petrie, 
2013). In addition, there is a clinical impression that some patient reported side-effects may in 
fact be disease symptoms (Thiwan et al., 2009) or common symptoms (Barsky, Saintfort, 
Rogers, & Borus, 2002) that are falsely labeled as medication side-effects.  
Studies applying Leventhal’s Common Sense Model (CSM) of self-regulation indicate 
that cognitive representations of illness and treatment play a key role in how patients appraise 
symptoms and make causal attributions (Baumann, Cameron, Zimmerman, & Leventhal, 1989; 
Cooper, Gellaitry, Hankins, Fisher, & Horne, 2009; Horne, 2003; Leventhal, Nerenz, & Straus, 
1982). According to the CSM, cognitive representations of illness have five core dimensions: 
identity (e.g. disease label, representation of typical symptoms), cause of the illness, perceived 
control over the illness (e.g. responsiveness to pharmaceutical treatment) and the severity of 
illness consequences. These dimension influence emotional and cognitive responses to illness 
and coping behaviours. This model has been extended (Horne, 2003) to include cognitive 
representations of treatment, which have been shown to influence how patients cope with illness 
and engage with treatment. For example, medication adherence is influenced by cognitive 
representations of specific medicines (Horne, Chapman, et al., 2013) and more general 
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‘background’ beliefs about pharmaceuticals as a class of treatment (Horne, Parham, Driscoll, & 
Robinson, 2009; Horne, Weinman, & Hankins, 1999).  
These background beliefs about medicines in general can be thought of as pharmaceutical 
schemas; how our ideas about pharmaceuticals are organized. Pharmaceutical schemas can be 
operationalized as ideas about medicines as objects (e.g. the degree to which they are generally 
harmful, beneficial, overused by doctors, etc. (Horne et al., 1999)) and beliefs about self in 
relation to medicines (e.g. beliefs about personal sensitivity to medicines (Horne et al., 1999)). 
Pharmaceutical schemas influence our evaluation of specific medicines (e.g. our perceptions of 
the treatment’s value and risks). For example, people with more negative pharmaceutical 
schemas tend to report more concerns about potential harmful effects when considering a 
specific treatment (Horne et al., 2009; Horne et al., 1999).  
A previous analogue study found that the misattribution of a common symptom as a side-
effect was influenced by individuals’ cognitive representations of pharmaceutical treatment 
(XXXXX, 2015). Individuals were more likely to misattribute an unrelated headache symptom 
as a side-effect if they started out with more negative pharmaceutical schemas (perceiving 
pharmaceuticals to be generally harmful and less beneficial) and if they had stronger concerns 
about the medication. 
In this paper we explore in more detail the psychological processes linking 
pharmaceutical schemas to the attribution of symptoms as side-effects using an analogue design. 
The primary aim of the study is to investigate whether pharmaceutical schemas influence how 
individuals process and remember side-effect information and whether this in turn affects side-
effect attribution. We hypothesize that the attribution of a symptom to a medication side-effect 
will be more accurate when the patient has accurately remembered information they have been 
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given about the specific side-effects that are known to be associated with the particular 
medication.  
Participants in this analogue online study saw the patient information leaflet of a 
fictitious asthma medication, with a list of side-effects. Both recall and recognition memory for 
listed side-effects was examined in this study. Recall involves the retrieval and reproduction of 
remembered information from memory while recognition memory relates to the capacity to 
compare new information to information in memory (Zechmeister & Nyberg, 1982). Schemas 
have been shown to influence both recall and recognition (Graesser & Nakamura, 1984). For 
example in the Deese-Roedinger-McDermott-paradigm (Roediger & McDermott, 1995) 
individuals who were asked to recall a list of thematically related words (e.g. tired, dream, bed, 
duvet…) falsely recalled and recognized unlisted words (e.g. sleep, night) that were part of the 
activated schema. 
Both recall and recognition could be important in the perception and attribution of 
symptoms as side-effects: To recognize whether a new symptom (e.g. headache) is a side-effect, 
patients need to compare it with the information they hold in memory about side-effects, while 
recalling side-effect information may influence whether patients expect to experience certain 
side-effects.  
As a secondary aim we explore whether including information about medication efficacy 
influences side-effect attributions. Patient information leaflets tend to include mostly risk 
information (e.g. side-effects, warnings about contraindications and interactions with other 
drugs), but rarely mention any benefits (e.g. efficacy information) (Kitching, 1990). 
Research on risk perception suggests that people typically perceive products (including 
asthma and other prescription drugs (Slovic, Peters, Grana, Berger, & Dieck, 2007)) that offer 
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greater benefits as less risky (Alhakami & Slovic, 1994). Making benefits more salient could 
thus be potentially effective in decreasing perceived risk and reducing the likelihood that 
unrelated symptoms are attributed as medication side-effects. On the other hand there is a 
clinical impression that patients often perceive medicines as a two-edged sword, believing that 
greater potency of medicines comes at the price of greater adverse effects (Horne, 2003). 
The following research questions and hypotheses were examined. In line with findings 
from a previous analogue study (XXXXX, 2015) we hypothesized that individuals with more 
negative pre-existing pharmaceutical schemas (e.g. beliefs that medicines are generally harmful, 
high perceived sensitivity to their effects) would show an increased tendency to attribute an 
unrelated symptom (not listed in leaflet) as a side-effect . 
We further tested whether pre-existing negative pharmaceutical schemas influenced 
recall and recognition, as well as reading times for side-effect information. Better memory for 
side-effects from the leaflet was expected to reduce the likelihood that an unlisted symptom was 
attributed as a side-effect. 
In addition, we explored whether the inclusion of efficacy information had an effect on 
perceived risk and side-effect attribution.  
 
Method 
Design 
This analogue online study used a randomized between group design (efficacy 
information versus no efficacy information). 
Participants and Recruitment 
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Adults (18 and over) with and without self-reported asthma were recruited via the 
Crowdflower crowdsourcing platform, from where they were directed to the Qualtrics online 
study. Crowdflower allows subscribers to post surveys that are then completed by “crowd 
workers” from online job boards (e.g. Amazon MTurk) for a small monetary reward (here 
$0.30). Only one survey submission from the same IP address (in this study or a related previous 
study (XXXXX, 2015) was permitted to ensure independence of responses. This type of 
sampling has proved reliable in studies of decision making and health (Buhrmester, Kwang, & 
Gosling, 2011; Ritter, Lorig, Laurent, & Matthews, 2004; Shapiro, Chandler, & Mueller, 2013). 
Measures and Materials 
Beliefs about Medicines Questionnaire-General 
The Beliefs about Medicines Questionnaire-General (BMQ-General) (Horne et al., 1999) 
assesses individuals’ beliefs about pharmaceutical medicines as a class of treatment on three 
scales, containing four items each. General Harm assesses the degree to which pharmaceuticals 
are perceived to be essentially harmful, addictive substances that are best avoided (e.g. 
“Medicines do more harm than good”). General Overuse assesses views about whether doctors 
place too much emphasis and trust on medicines (e.g. “If doctors had more time with patients 
they would prescribe fewer medicines”). General Benefit captures perceptions of medicines as 
fundamentally beneficial (e.g. “Medicines help many people to live better lives.”). 
Perceived Sensitivity to Medicines Scale 
The Perceived Sensitivity to Medicines Scale (PSM) (Horne, Faasse, et al., 2013) assesses 
beliefs about the self in relation to medicines; specifically about personal sensitivity to the 
positive and negative effects of medicines (e.g. “My body overreacts to medicine.”) with five 
scale items. 
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All BMQ and PSM items were rated on 5-point Likert-type scales (from 1=strongly disagree to 
5=strongly agree). Mean scale scores were computed by summing scale item scores and dividing 
the total by the number of scale items. Higher scale scores indicate higher endorsement of the 
scale construct. The BMQ and PSM scales have shown good reliability and validity in previous 
studies (Horne et al., 1999). Internal consistency of all scales in this study was good (Cronbach’s 
αs >.75). 
Demographics and self-reported asthma diagnosis 
Participants indicated their age, gender, ethnicity, country of residence, and whether they had 
ever been diagnosed with asthma and previously taken asthma medication. 
Asthma Information 
Participants read information about asthma, structured according to Leventhal’s common sense 
model of illness representation (Diefenbach & Leventhal, 1996). It included information about 
asthma causes and triggers, symptoms and their episodic nature, likely consequences, and asthma 
management (see XXXXX, 2015).  
Molair Patient Information Leaflets 
Participants read one of two possible patient leaflets of the fictitious asthma medication Molair, 
modelled on the existing asthma drug Montelukast (see Figure 1). The Qualtrics block 
randomization function was used to randomize participants to leaflet conditions. [Figure 1 near 
here] 
 Both information leaflets provided information about Molair’s mechanism of action 
(leukotriene receptor agonist) on the first page. Possible side-effects (rash, dizziness; 
yellowing of the skin, itch, fatigue, abdominal pain, joint pain, muscle pain) were listed on a 
separate page. The order of side-effects was randomised.  
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 The “Efficacy information” leaflet contained an additional page outlining Molair’s efficacy 
(based on a clinical trial of Montelukast (Virchow & Bachert, 2006)) presented before the 
side-effect information:“A recent clinical trial (with 5855 asthma patients) has shown the 
effectiveness of Molair in adults. Following a 4-6 week treatment with Molair 86.6% percent 
of patients reported a strong improvement in day-time asthma symptoms and 88.7% a strong 
improvement in night-time asthma symptoms.” 
Reading times for Side-Effect Information 
The Qualtrics page timing function was used to measure how long participant spent on the 
side-effect information page. 
Efficacy and Side-Effect Expectation Visual Analogue Scales (VAS) 
Three 100-point VAS were used to measure perceptions of efficacy (e.g. How effective do 
you think Molair is in general for the prevention of asthma symptoms? Rated from 0=not 
effective at all to 100=extremely effective). Four 100-point VAS assessed side-effect 
expectations (e.g. How frequently do you think people in general develop side-effects when 
taking Molair? Rated from 0=never to 100=always). Mean scores were computed for both 
sets of VAS. Internal consistency for both sets of VAS was high (Cronbach’s α of .88 and .90 
respectively). 
Recall Task 
Participants were asked to type all the side-effects they could remember from the leaflet. 
Responses were coded by XXX as correct if they matched or were synonyms (e.g. tiredness for 
fatigue) of listed side-effects and incorrect if they were not listed. Correct Side-Effect Recall and 
Incorrect Side-Effect Recall scores were computed by counting correct and incorrect responses 
respectively. 
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Recognition Task 
Participants saw a table with 16 symptoms in randomized order (see Figure 2): 8 side-effects 
from the leaflet, 8 new symptoms. Listed side-effects and new symptoms were matched in word 
length (t(14)=.560, p=.586). A post-test with n=33 participants, recruited as per the main study, 
found no difference in perceived severity (t(32)=.08, p=.941). Participants were asked to indicate 
(yes/no) whether each symptom had been listed in the leaflet. Correct Side-Effect Recognition 
and Incorrect Side-Effect-Recognition scores were computed by counting the number of 
correctly and incorrectly recognized side-effects. [Figure 2 near here] 
In addition, we computed more sophisticated recognition memory indices in line with 
Signal Detection Theory (SDT) (Green & Swets, 1966; McNicol, 2005). According to SDT, 
whether a participant responds that a symptom was listed in the leaflet will depend both on the 
memory strength of the symptom and the participant’s general tendency to guess that a symptom 
was listed (Response Bias). Responses were coded as Correct Hits (responded listed, when 
listed), Correct Rejections (responded new, when new), Misses (responded new, when listed), 
and False Alarms (responded listed, when new). False Alarm rates (number of False 
Alarms/number of new symptoms) and Correct Hit rates (number of correct hits/number of listed 
side-effects) were calculated. From these Response Bias (tendency to guess that a symptom was 
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listed) and Side-Effect Recognition Sensitivity (ability to discriminate between listed side-effects 
and new symptoms) were calculated1: 
 Side-Effect Recognition Sensitivity was operationalized as the difference between the z-
scores of the Correct Hit and False Alarm rates (Stanislaw & Todorov, 1999). Low 
Recognition Sensitivity could arise if a participant strategically responds all items were from 
the memorized list, resulting in a perfect Correct Hit rate and maximum False Alarm rate. 
Higher Side-Effect Recognition Sensitivity indicates better discrimination between 
previously listed side-effects and new symptoms. 
 Response Bias was computed by summing the z-score corresponding to the False Alarm and 
the Correct Hit rate and multiplying the result by -1/2. (Macmillan, 1993). Higher Response 
Bias scores indicate more conservative responding i.e. decreased willingness to guess that an 
item was from the original list. 
 
Symptom Attribution Vignette 
Participants read the following vignette: “Imagine you are suffering from asthma. You have been 
taking one 4mg tablet of Molair every day for the last two weeks. At the beginning of the third 
week you get a headache.” Headache was not listed as one of Molair’s side-effects in the leaflet. 
Participants were then asked to indicate on 100-point visual analogue scales how likely they 
thought that six different factors (side-effect of Molair, eye strain, stress, beginning of a cold, 
                                                     
 
1 Extreme Correct Hit and False Alarm rates of 0 and 1, which would result in infinite parameter estimates 
were adjusted. Rates of 0 were replaced with 0.5/n and rates of 1 with (n-0.5)/n, where n is the number of listed and 
new symptoms respectively (Macmillan & Kaplan, 1985). 
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lack of sleep, no particular reason; order randomized) caused the headache (from 0= very 
unlikely to 100=very likely).  
 
Procedures 
The study was categorized as exempt from ethical approval by the xxxx Research Ethics 
Committee. Data was collected online with Qualtrics survey software 
(http://www.qualtrics.com). Participants gave informed consent, completed the PSM and the 
BMQ-General, read the asthma information and were randomized to leaflet conditions using the 
Qualtrics block randomization function. Participants then completed the Side-effect and Efficacy 
Expectation VAS and the Recall and Recognition Tasks (fixed order). Finally participants 
completed the Symptom Attribution Vignette, Demographics and Self-Reported Asthma 
Diagnosis questions and received a short written debriefing statement. 
 
Statistical considerations 
Sample size was calculated with GPower version 3.1. based on previously published data 
(XXXXX, 2015), showing that 244 participants were required to predict side-effect attribution in 
a multivariate linear regression model with four predictors. Pearson correlations were used to 
explore relationships between pharmaceutical schemas, side-effect attribution, and memory 
outcomes.  
The frequency and distribution of memory outcomes (Correct Side-Effect Recall, 
Incorrect Side-Effect Recall, Recognition Sensitivity, Criterion Bias) was examined. Incorrect 
Side-Effect Recall was rare and outcomes were dichotomized (any incorrect recall yes/no). 
Associations between pharmaceutical schemas and dichotomized Incorrect Side-Effect Recall 
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were examined using logistic regression. Linear regression modeling was used to model 
associations between pharmaceutical schemas and side-effect attribution and all other memory 
related outcomes. Hierarchical linear regression modeling was used to explore the amount of 
variance explained by pharmaceutical schemas in these outcomes when controlling for leaflet 
condition, asthma diagnosis, gender and age. 
Putative associations between pharmaceutical schemas and reading times for side-effect 
information and between memory outcomes and side-effect attribution were examined using 
correlational analysis and linear regression. 
Correct recall and recognition sensitivity were examined as potential mediators in the 
relationship between pharmaceutical schemas and side-effect attribution using bootstrapped 
confidence intervals (1000 bootstrap samples) of the estimated indirect effect using the 
PROCESS Macro for SPSS (Hayes, 2012).  
Differences in expectations, side-effect attribution and memory outcomes between 
participants randomized to the different leaflet conditions were examined with independent t-
tests. 
 
Results 
Survey Completion Rates and Data Exclusions 
Responses from the same IP address (n=29), and responses with incomplete outcome data 
(n=33) were excluded. Pharmaceutical schemas did not differ between completers and non-
completers (ps>.12). Data from 260 participants was retained. 
Demographic characteristics and reported asthma diagnosis  
Participants were predominantly white (74.2%), female (58.8%), US residents (94.1%) 
without a reported asthma diagnosis (77.7%) (see Table 1).  
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[Table 1 near here] 
Inter-correlations between pharmaceutical schemas 
There were small to moderate correlations between individual measures assessing 
pharmaceutical schemas (see Table 2). Participants, who believed pharmaceutical medicines to 
be more harmful, perceived pharmaceuticals as less beneficial and overprescribed by doctors and 
perceived themselves as more sensitive to their effect.  
[insert Table 2 around here]. 
 
Descriptive memory outcomes 
Participants recalled on average only 2 of the 8 listed PIL side-effects (Correct Side-
Effect Recall, see Table 2). Around a fourth of participants (24.3%) recalled at least one unlisted 
side-effect (Incorrect Side-Effect Recall). Correct and Incorrect Side-Effect Recall were 
significantly negatively correlated (r=-.134, p<.05), indicating that participants who recalled 
more side-effects correctly committed less recall errors. 
Participants recognized on average five listed (M=5.45, SD= 1.87) and two unlisted side-
effects (M=2.08, SD=2.00). Over three quarters of participants (75.4%) “recognized” at least one 
unlisted side-effect. Mean Side-Effect Recognition Sensitivity was 1.24 (SD=1.12). The mean 
Response Bias (M=0.09, SD=0.48) was above 0, indicating that participants were unwilling to 
guess that side-effects were from the leaflet. 
Pharmaceutical schemas and side-effect attribution 
Exploratory analyses showed that participants rated the headache symptom as more likely 
to be a side-effect of Molair if they believed medicines to be more harmful, overused, and less 
beneficial and perceived themselves as more sensitive to medicines (see Table 2). Demographic 
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factors, leaflet condition and self-reported asthma diagnosis showed no association with side-
effect attribution (all ps>.05). A multivariate linear regression model with BMQ-General scales 
and PSM entered jointly in the model explained 16.8% of variance in side-effect attribution 
(F(4)=14.09, p<.001). Both PSM (β=.172) and General Harm (β=.296, ps<.01) remained 
significant predictors in the multivariate model, while General Benefit was only marginally 
significant (β=-.100, p=.096).  
 
Pharmaceutical schemas and memory for side-effect information 
Correct Side-Effect Recall 
Exploratory analyses (see Table 2) showed that there were significant correlations 
between BMQ-General Benefit and Harm beliefs and Correct Side-Effect Recall. Stronger 
beliefs in the harmfulness of pharmaceuticals were associated with reduced Correct Side-Effect 
Recall (r=-.273), whereas stronger perceived benefits of pharmaceuticals were associated with 
increased Correct Side-Effect Recall (r=.164, ps<.01). Perceived Sensitivity to Medicines (PSM) 
and beliefs that medicines are overprescribed by doctors (BMQ-General Overuse) were not 
associated with Correct Side-Effect Recall. Figure 3 illustrates differences in Correct Side-Effect 
Recall for participants scoring in the lower and upper 50th percentile (Median split) on the 
General Harm and General Benefit scales. [Figure 3 near here] 
A hierarchical regression model was then constructed to test for the amount of variance in 
Correct Side-Effect Recall explained by pharmaceutical schemas, when controlling for age, 
gender, asthma diagnosis and leaflet condition (see Table 3, Model A). In this model both control 
variables (R2 step 1=.066, p<.01) and pharmaceutical schemas (R2 change step 2=.082, p<.001) 
significantly improved prediction. General Harm beliefs remained a significant predictor (β =-
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.340, p<.001) in the multivariate model. Probably owing to relatively high inter-correlations 
between beliefs (see Table 2), General benefit beliefs failed to reach significance in the full 
model.  
 
Incorrect Side-Effect Recall 
Exploratory analyses showed no associations between pharmaceutical schemas and the 
number of incorrectly recalled side-effects (see Table 2). Univariate logistic regression models 
predicting dichotomized Incorrect Recall also found no associations with pharmaceutical 
schemas or control variables (all confidence intervals of ORs contained zero). 
Recognition Sensitivity 
Exploratory correlational analyses showed that General Harm and General Benefit beliefs 
were also significantly associated with participants’ ability to discriminate side-effects from the 
leaflet from new unlisted symptoms (Recognition Sensitivity). Stronger General Harm beliefs 
were associated with reduced Recognition Sensitivity (r=-.256, p<.01), stronger beliefs in the 
benefits of medicines were associated with increased Recognition Sensitivity (r=.160, p<.05). 
A hierarchical linear regression model, with all control variables entered in the first step 
and pharmaceutical schemas entered in the second step (see Table 3, Model B) showed that 
recognition sensitivity was better for women and older participants, with control variables 
accounting for around 10% of variance in Recognition Sensitivity. Adding pharmaceutical 
schemas to the model significantly improved prediction, accounting for an additional 8.7% of 
variance (see Table 3, Model B). 
Response Bias 
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Exploratory analysis (see Table 2) showed that General Harm (r=.126; p<.05), General 
Benefit (r=.215, p<.001) and General Overuse beliefs (r=.223, p<.001), were associated with 
higher Response Bias, indicating that participants with this belief set were less likely to guess 
that a symptom was from the leaflet. A hierarchical linear regression model (again with control 
variables entered in Step 1 and pharmaceutical schemas entered in step 2) found that control 
variables were not associated with Response Bias (R2=.012, p>.05), whereas pharmaceutical 
schemas accounted for 10% of variance (see Table 3, Model C). 
 
Memory for side-effect information and side-effect attribution 
Univariate linear regression models tested whether more accurate memory for side-
effects from the leaflet reduced attribution of an unlisted symptom as a side-effect. As predicted, 
Correct Side-Effect Recall (β =-.234) and Recognition Sensitivity significantly reduced side-
effect attribution (β =-.207, ps<.001). Response Bias (β =-.019, p=.762) and Incorrect Side-
Effect Recall (β =-.017, p=.789) were not associated with side-effect attribution (see also Table 
2). 
Mediation analysis 
Mediation analysis was used to examine whether the effect of pharmaceutical schemas on 
side-effect attribution was mediated by memory for side-effect information. We only tested for 
mediation effects for General Harm and Benefit beliefs, as there were no direct effects of either 
PSM or Overuse on Correct Side Effect Recall and Recognition Sensitivity (see Table 2). A 
mediation model with General Harm beliefs as predictor, Correct Side-Effect Recall as 
mediating variable and side-effect attribution as outcome (see Figure 4a), showed that Correct 
Side-Effect Recall significantly mediated the effect of General Harm beliefs on side-effect 
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attribution (indirect effect ab=1.23; 95% CI [0.20; 2.65]; R2 mediation effect size=.03; 95% CI 
[.01, .07]). The direct effect of Harm beliefs on attribution remained significant (c’=10.76; 95% 
CI [7.00, 14.51], p<.001), suggesting partial mediation. An equivalent mediation model was 
constructed for General Benefit beliefs (see Figure 3b). In this model Correct Recall again 
significantly mediated the relationship with the bootstrapped confidence interval of the indirect 
effect again excluding zero (indirect effect ab=-1.36; 95% CI [-2.98; -0.38]; R2 mediation effect 
size=.01; 95% CI [.002, .032]). As in the previous model, the direct effect of Benefit beliefs on 
attribution was significant (c’=-7.53 95% CI [-12.37, -2.69], p<.01). Findings were similar when 
using recognition sensitivity as a mediator in models 4a and 4b, with both confidence intervals of 
the indirect effect excluding zero. [Figures 4a and 4b near here] 
Pharmaceutical schemas and reading times 
Participants who believed medicines to be more harmful (β=-.128) and who perceived 
themselves as more sensitive to their effects (β=-.138, ps<.05) spent less time reading side-effect 
information (all other BMQ-scales ps>.05). Older participants spent longer reading side-effect 
information (β=.292, p<.001), but there was no difference between men and women (β=.03, 
p=.61) and participants with or without self-reported asthma (β=.03, p=.66) or any of the other 
control variables. 
Testing for differences between leaflet conditions 
Demographic characteristics were similar in both leaflet conditions (ps>.05). Participants 
in the efficacy information leaflet condition rated Molair as significantly more effective than 
participants in the no efficacy information condition (t(258)=2.17, p<.05; see Table 4 for means). 
As shown by previous regression analyses there was no significant difference in side-effect 
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expectations, memory outcomes or side-effect attribution between the two groups (all ts<1, 
ps>.05, see Table 4). [Table 4 near here] 
Discussion 
In line with previous findings (XXXXX, 2015), we found that more negative 
pharmaceutical schemas (beliefs that pharmaceutical medicines are harmful, less beneficial and 
high perceived sensitivity to medicines) were associated with increased attribution of an 
unrelated symptom (not listed in the patient leaflet) as a side-effect. But this was the first study to 
show the role of pharmaceutical schemas in memory for side-effect information: Participants 
who perceived pharmaceuticals as more harmful recalled fewer listed side-effects and were less 
able to discriminate between listed and new side-effects in the recognition memory task 
(Recognition Sensitivity). Pharmaceutical schemas accounted for around 8% of variance in both 
Recognition Sensitivity and in the number of correctly recalled side-effects, when controlling for 
previous asthma diagnosis, age, gender and leaflet condition.  
As predicted, better memory for listed side-effects decreased the likelihood that an 
unlisted symptom was attributed as a side-effect. The relationship between pharmaceutical 
schemas and side-effect attribution was partially mediated by memory for side-effect 
information. While including efficacy information in one version of the patient leaflet increased 
individuals’ expectations of the drug’s efficacy, it did not affect side-effect expectations, 
memory for side-effect information or side-effect attribution. 
Previous studies have shown poor memory for medical information (Barsky, 2002; Ley, 
1979), but few have examined potentially modifiable psychological factors related to memory 
(Watson & McKinstry, 2009) and linked memory for side-effects to symptom attribution 
decisions. There is evidence that illness schemas influence recall of illness symptoms (Baumann 
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et al., 1989), but few other studies have examined the role of schemas in memory for side-
effects. Previous studies have for example shown that older adults, who may have more detailed 
side effect schemas, correctly recalled more severe than mild side effects, but had problems in 
recognizing important side effects that required actions (“contact your doctor if you experience 
this”) relative to younger participants (Friedman, McGillivray, Murayama, & Castel, 2015).  
Perhaps contrary to clinical intuition, participants who worried more about the potential 
harmfulness of pharmaceuticals showed poorer memory for side-effect information (reduced 
Correct Side Effect Recall and Recognition Sensitivity).  
Possible reasons for this unexpected finding include avoidance of information and gist-
based encoding. Participants with stronger harm beliefs spent less time on the page containing 
the side-effect information, suggesting the may have paid less attention, resulting in poorer 
memory for side-effects. This is in line with studies that show that anxious people may avoid 
anxiety inducing stimuli (Cisler, Bacon, & Williams, 2009; Onnis, Dadds, & Bryant, 2011) and 
qualitative studies where patients report actively avoiding information about side-effects, to 
prevent becoming frightened and demotivated to take their treatment (Hayden, Neame, & 
Tarrant, 2015). Information about side-effects may also have confirmed participants’ negative 
preconceptions about medicines, leading them to scrutinize information less, encode only the 
general gist (Brainerd & Reyna, 2002; Reyna & Brainerd, 1995) or to rely on existing schema 
when performing the memory tasks. Harm beliefs were associated with reduced recognition 
sensitivity (indicating more false alarms) supporting the use of gist-based memory strategies 
(Roediger & McDermott, 1995). 
Some participants were randomized to receive information efficacy in the patient leaflet, 
after completing the belief measures. According to the affect heuristic (Slovic, Finucane, Peters, 
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& MacGregor, 2007), higher efficacy perceptions should lead to more positive feelings about the 
treatment and reduced risk perceptions. The inclusion of efficacy information in the leaflet 
significantly increased efficacy expectations, but did not affect risk perceptions or side-effect 
attribution or memory outcomes. Possibly the manipulation (adding one paragraph to an online 
patient leaflet) was too weak to raise efficacy expectations enough as to impact risk perception.  
The study also clearly highlights the role of side-effect memory in symptom attribution. 
People are more likely to make appropriate symptom attribution decisions if they correctly 
remember side-effect information. Better memory for factual side-effect information may reduce 
the likelihood that noisy common background symptoms (Reidenberg & Lowenthal, 1968) or 
symptoms of the disease (Thiwan et al., 2009) are reported as side-effects. The misattribution of 
unrelated symptoms as side-effects is problematic as it may increase non-adherence intentions 
(XXXXX, 2015) and could reinforce pre-existing negative pharmaceutical schemas. 
The study has several strengths and limitations. The analogue study approach, using a 
fictitious (but realistic) medication allowed us to control for previous experience with the 
medication and to unambiguously operationalize what constitutes an unrelated side-effect. Recall 
and recognition memory was similar for participants with and without self-reported past asthma 
diagnosis, speaking to the potential generalizability of findings.  
It was beyond the scope of this preliminary online study to assess other potentially 
important variables (e.g. health anxiety, somatization, illness representations, and previous side-
effect experience). Recall and recognition memory were measured within subjects, raising the 
possibility that recognition was influenced by previous recall. A replication of the findings, 
varying recall and recognition between subjects, is needed. Future studies should also explore 
whether pharmaceutical schemas are only associated with reduced memory for side-effect 
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information and not memory in general (e.g. by including a standardized memory test (e.g. 
Wechsler Digit Span Test(Wechsler, 2008)). Participants with more negative pharmaceutical 
schemas may have differed systematically on memory-relevant attributes such as educational 
background and need for cognition from participants with more positive schemas. Further studies 
could test whether there was a specific effect of schemas on memory rather than these factors, by 
attempting to modify pharmaceutical schemas and examining whether this affects memory for 
side effects. However, changing peoples’ ingrained beliefs about pharmaceuticals may not be 
straightforward, particular in an online setting. Even relatively intensive interventions (e.g. 
individual sessions with a nurse (Chapman et al., 2015)) to change beliefs about prescribed 
medications and improve adherence have had mixed success (Chapman et al., 2015; Petrie, 
Perry, Broadbent, & Weinman, 2012; Zwikker et al., 2014). 
The role of attentional processes in the association between medication beliefs and 
memory for treatment information also merits further investigation. Our finding that participants 
with negative medication beliefs spent less time reading side-effect information rests on online 
data, where a range of uncontrolled variables may have affected reading time. We also recognize 
that analogue studies have only limited external validity and that involvement of participants was 
probably low (e.g. participants recalled on average only 2 of 8 listed side-effects). However 
patient information leaflets are also often poorly read (Grime, Blenkinsopp, Raynor, Pollock, & 
Knapp, 2007) and recalled (Kessels, 2003) in clinical practice. A replication of the findings in 
clinical samples, prescribed real medication, with a range of mild to severe side-effects is 
nevertheless highly warranted. 
If replicated in clinical samples, our findings suggest that discussions and information 
about potential side-effects could be individualized to take account of pre-exiting pharmaceutical 
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schemas to improve memory for side-effect information. Despite the limitations inherent in an 
analogue study our findings provide new knowledge about the psychological processes linking 
medicines information to the attribution of symptoms as medication side-effects by showing that 
pre-existing pharmaceutical schemas affect both the quantity and accuracy of memory for side-
effect information.  
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Tables 
Table 1: Sample characteristics 
Variable N=260 
Age in years mean (SD) 34.7 
(11.6) 
Gender n (%)  
   Female 153 
(58.8) 
 
 
Ethnicity n (%)  
   White American 177 
(68.1) 
   White British/ Irish 16 (6.2) 
   Black 13 (5.0) 
   Indian/Pakistani/Bangladeshi 8 (3.1) 
First Language n (%) 
   English 242 
(93.1) 
Residence n (%)  
   United States 241 
(94.1) 
Asthma n (%)  
   reported diagnosis 
 
58 (22.3) 
   taken asthma medication 52 (20.0) 
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Table 2: Correlations between pharmaceutical schemas, side effect attribution and memory 
outcomes 
  1  2  3  4  5  6  7  8  9 M (SD) 
1 PSM;   1  .34** -.13*  .28**  .28** -.07  .08 -.03  .06 2.6 (1.0) 
2 General Harm;    1 -
.32** 
 .57**  .38** -
.27** 
-.01 -
.27** 
 .13* 2.5 (0.8) 
3 General Benefit;     1 -
.16** 
-
.22** 
 .16** -.04  .16*  .22** 3.8 (0.7) 
4 General Overuse;      1  .22**  .03 -.02  .07  .22** 3.4 (0.8) 
5 SE Attribution      1 -
.23** 
-.02 -
.20** 
-.02 39.6 (26.2) 
6 Correct SE Recall;        1 -.13*  .72**  .03 2.2 (1.6) 
7 Incorrect SE Recall         1 -
.21** 
-
.16** 
0.3 (0.4) 
8 Recognition Sensitivity         1  .07 1.2 (1.1) 
9 Criterion Bias           1 0.10 (0.5) 
Note. ** p<.01; * p<.05 (both two-tailed) 
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Table 3: Hierarchical regression models predicting Correct and Incorrect Side Effect Recall 
 
 Model A 
Correct Side Effect 
Recall 
 Model B 
Recognition Sensitivity 
 Model C 
Response Bias 
 R2 β  R2 β  R2 β 
Step 1 .066**  .101***   .012 
   Leaflet Condition 
   Asthma1 
   Gender2 
   Age 
 -.028 
-.056 
 .183** 
.146* 
  .017 
-.043 
 .187** 
 .226*** 
  -.024 
 .069 
 .030 
 .061 
 
Step 2 .082***  .087***   .089*** 
   General Harm 
   General Benefit 
   General Overuse 
   PSM 
 -.340*** 
.048 
.202** 
-.014 
  -.367*** 
.038 
.238** 
.013 
  .110 
 .238*** 
 .191* 
 .003 
Total R2 .147***  .188***   .102*** 
 
Note. ***p<.001; **p<.01; *p<.05; PSM=Perceived Sensitivity to Medicines Scale, 1,2reference 
category= reported asthma diagnosis, male,   
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Table 4: Expectations and Memory outcomes by leaflet condition  
Variable Efficacy 
Information 
(n=133) 
No Efficacy 
Information  
(n=127) 
Total 
(N=260) 
p-value  
Expectations 
Side Effect VAS; M(SD) 
Efficacy VAS; M (SD) 
 
 
44.19 (23.25) 
70.79 (18.08) 
 
41.81 (22.71) 
66.27 (15.40) 
 
43.03 (22.98) 
68.58 (16.94) 
 
.405 
<.05 
Memory Outcomes 
Correct SE Recall M (SD) 
 
2.24 (1.68) 
 
2.18 (1.60) 
 
2.21 (1.63) 
 
.764 
Correct SE Recognition M (SD) 5.44 (2.00) 5.45 (1.74) 5.45 (1.87) .931 
Incorrect SE Recall M (SD) 0.27 (0.52) 0.35 (0.67) 0.31 (0.36) .411 a 
Incorrect SE Recognition M (SD) 2.10 (2.00) 
 
2.07 (1.92) 
 
2.08 (2.00) 
 
.820 
Side effect attribution M (SD) 39.23 (27.54) 39.98 (24.89) 39.60 (26.23) .816 
Note. SE=Side effect; VAS=Visual Analogue Scale; a Pearson χ2-Test; all other tests independent samples 
t-test (all two-sided) 
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Figure captions 
 
Figure 1: Molair Patient Information Leaflet 
[Figure 1] 
 
Note. Dotted lines represent page breaks. Efficacy information on (Page 2) was only 
presented in the “Efficacy information” leaflet condition. 
 
 
Figure 2: Side Effect Recognition Task 
[Figure 2] 
 
 
Figure 3: Mean Correct Side Effect Recall for participants with high and low General Harm and 
Benefit Beliefs 
[Figure 3] 
Note. **p<.01; SE=side effect; low/high General Harm/Benefit scores determined by 
median split; error bars represent Standard Errors  
 
 
Figure 4: Correct Recall mediates relationship between General Harm and General Benefit beliefs 
and side effect attribution  
 
[Figure 4a] 
[Figure 4b] 
 
 
